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Blinatumomab has shown efficacy in B-cell malignancies.1–3 Rapid
clearance of peripheral B cells has been demonstrated, resulting in
sustained B-cell depletion throughout the treatment period.1–3
This report describes serum immunoglobulin levels during and
after blinatumomab treatment in a phase 2 study in patients with
minimal residual disease (MRD) of B-precursor acute lympho-
blastic leukemia (ALL).2,3
The study followed an open-label, multicenter, single-arm, phase 2
design. Study details and primary analysis data have been described
previously.3 Briefly, patients with positive MRD status (410−4
detectable blast cells using quantitative PCR) at any time after
induction and consolidation therapy according to German multi-
center study group for adult ALL (GMALL) protocols were eligible.
The primary objective was to determine the efficacy of blinatumo-
mab in patients with MRD-positive B-precursor ALL. Patients received
blinatumomab as a continuous intravenous infusion at a dose of
15 μg/m2/day over 4 weeks, followed by a 2-week treatment-free
period (6-week cycles). For patients with an allogeneic donor, an
allogeneic hematopoietic stem cell transplantation (HSCT) was
offered at any time after the first 6-week cycle. Responders could
receive three additional consolidation cycles of blinatumomab
treatment. Between May 2008 and November 2009, 21 patients
with MRD-positive B-precursor ALL were treated.
Serum immunoglobulins IgM, IgG, IgA and IgE have a
central role in the humoral immune response by binding to
extracellular pathogens, thereby activating the complement
system along with effector cells, which ultimately leads to
pathogen eradication.4 Whereas serum IgM antibodies are
mainly produced during a primary immune response by plasma
cells originating from activated naive B cells, IgG, IgA, and IgE are
also secreted in large amounts during secondary immune responses
by plasma cells originating from activated memory B cells. Most
long-lived antibody-based immunity against invading pathogens is
provided by serum IgG and mucosal IgA. Hence, therapy-induced
depletion of CD19-positive B cells and plasma blasts, and associated
subsequent decline of plasma cells can result in a long-term
decrease of serum immunoglobulin concentrations, which recover
only after regeneration of naive and memory B cells from CD19-
negative hematopoietic B-cell progenitors. Patients receiving
B-cell–depleting therapies may therefore be susceptible to severe
infections during and after treatment.
In our phase 2 study, IgM, IgG, IgA and IgE levels were
monitored during a follow-up time ranging from 255 to 1605 days
(median, 457.5 days) in six patients with MRD-positive B-precursor
ALL who did not receive HSCT after blinatumomab treatment.
Four of the six patients had Philadelphia chromosome
Table 1. Serum immunoglobulin levels of individual patients at various time points during the study
Patient identifier Time point of
measurement
IgA mg/dl IgG mg/dl IgM mg/dl Tyrosine kinase inhibitor
treatment post blinatumomab
Reference range (70–400) (700–1600) (40–230)
111–006a Screening 217 (100%) 629 (100%) 66 (100%) None
Lowest value 13 (6%) 232 (37%) 8 (12%)
Last FU 13 (6%) 250 (40%) 49 (60%)
113–002a Screening 58 (100%) 457 (100%) 111( 100%) None
Lowest value 21 (36%) 210 (40%) 37 (33%)
Last FU 37 (64%) 320 (70%) 72 (65%)
109–007a Screening 132 (100%) 830 (100%) 103 (100%) None
Lowest value 16 (13%) 242 (29%) 29 (28%)
Last FU 58 (44%) 801 (97%) 100 (97%)
108–001a Screening 64 (100%) 700 (100%) 58 (100%) None
Lowest value 15 (33%) 296 (42%) 24 (41%)
Last FU 30 (47%) 789 (113%) 137 (236%)
110–002b,c Screening 54 (100%) 330 (100%) 31 (100%) Imatinib, dasatinib
Lowest value 20 (39%) 333 (101%) 14 (45%)
Last FU 26 (48%) 333 (101%) 14 (45%)
111–003b Screening 178 (100%) 696 (100%) 38 (100%) Imatinib
Lowest value 13 (35%) 234 (34%) 9 (24%)
Last FU 63 (73%) 487 (70%) 36 (91%)
Abbreviation: FU, follow-up. Percentages are normalized to respective baseline values. ‘Screening’ indicates baseline. aPhiladelphia chromosome-negative.
bPhiladelphia-chromosome positive. cnonresponder (no MRD response).
Citation: Blood Cancer Journal (2014) 4, 244; doi:10.1038/bcj.2014.64
© 2014 Macmillan Publishers Limited All rights reserved 2044-5385/14
www.nature.com/bcj
(Ph)-negative ALL; two had Ph-positive ALL. After completion of
blinatumomab treatment, the four patients with Ph-negative ALL
did not receive any further treatment for their disease, whereas
the two patients with Ph-positive ALL received tyrosine kinase
inhibitors. One of the two patients with Ph-positive ALL had no
MRD response at the end of blinatumomab treatment (Table 1).
The five responders received blinatumomab for a median of
154 days (infusion period plus treatment-free period); the
nonresponder was treated for 287 days. Three patients entered
the study with an IgA level, four with an IgG level, and two with an
IgM level below normal range. The most pronounced immuno-
globulin decrease was observed for IgA, with a decline to 6%
(range, 6–39%) of baseline in response to blinatumomab
treatment (Figures 1a–d; Table 1). The lowest levels of IgM and
IgG were 12% (range, 12–45%) and 29% (range, 29–101%) of
baseline, respectively. In the five responders, the median time to
lowest level was 168 days for IgA, 126 days for IgM, and 260 days
for IgG. In the nonresponder, this time was 112 days for IgA, and
245 days for IgM. IgG levels in the nonresponder did not decrease
in response to blinatumomab treatment. None of the five
responders showed a return of serum IgA levels to baseline after
blinatumomab treatment, but in two responders the IgA recovery
exceeded 50% of baseline. One of the five responders showed a
recovery of both serum IgG and IgM levels to above baseline, and
IgG and IgM recovery exceeded 50% in three and four of the other
responders, respectively. The nonresponder presented with less
than 50% recovery of both IgA and IgM, whereas serum IgG levels
were not decreased by blinatumomab treatment.
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Figure 1. Serum immunoglobulin levels over time in a phase 2 study of blinatumomab in patients with MRD-positive B-precursor acute
lymphoblastic leukemia (ALL). Panels show data for serum IgM (a), IgG (b), IgA (c) and IgE (d) concentrations for five responders and one
nonresponder (Patient 110–002, indicated with an asterisk).
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Immunoglobulin levels and isotype recovery sequence
(IgM4IgG4IgA) in responders correlated with the expected
mode of action of blinatumomab, with initial B-cell depletion
leading to decreased immunoglobulin levels during and after
treatment and a subsequent return of IgM-secreting plasma cells
originating from newly developed naive B cells. However, in the
nonresponding patient, no reduction of IgG levels and a o50%
recovery of IgM levels were observed, suggesting incomplete
depletion of plasma blasts during, and diminished return of naive
B cells after, blinatumomab therapy. As described above, patients
in the current study had hypogammaglobulinemia at study entry,
stemming from prior front-line chemotherapy and/or the under-
lying ALL. Chemotherapy has known suppressive effects on
immunoglobulin levels, with IgM and IgG typically showing the
greatest decrease after treatment.5 Vincristine and prednisone
appear to have a major role specifically in the drop of IgG levels.5
Chemotherapy dose reductions can lessen immunoglobulin level
decreases and support recovery.5
As CD19, but not CD20, expression is maintained on plasma
blasts, anti-CD19 antibodies are predicted to induce a more
profound decrease of immunoglobulin levels than anti-CD20
antibodies.6 However, extensive clinical experience has shown
that the anti-CD20 monoclonal antibody rituximab may
decrease serum levels of immunoglobulins across various
disease settings. For example, in patients with anti-neutrophil
cytoplasmic autoantibody-associated vasculitis, rituximab may
exacerbate a cyclophosphamide-induced decline of immuno-
globulin levels.7 Similarly, data from two patients with idiopathic
thrombocytopenic purpura and pre-existing primary antibody
deficiency, who presented with recurrent infections immediately
following rituximab therapy, suggest exacerbation of the
underlying immune deficiency.8 In a study of patients with
newly diagnosed aggressive B-cell lymphoma, hypogammaglo-
bulinemia was present at the end of chemotherapy treatment
but resolved 12 months later. However, addition of rituximab
was associated with a more pronounced decline in immuno-
globulin levels than chemotherapy treatment alone, and that
decline was sustained 12 months after cessation of therapy.9
A cross-study analysis of data from 211 patients with B-cell
lymphoma who received rituximab treatment showed that
hypogammaglobulinemia developed in 38.5% and symptomatic
hypogammaglobulinemia (after multiple courses of treatment)
in 6.6% of patients.10 Two case reports have described
hypogammaglobulinemia that lasted for 6–7 years after
completion of rituximab-based treatment in patients with
follicular lymphoma.11,12 In one patient, who had normal
immunoglobulin concentrations at treatment start, the level of
IgG dropped to below 100 mg/dl, and both IgA and IgM
remained undetectable for 6 years after treatment stop, despite
recovery of peripheral B-cell counts.12 A second patient
presented with pan-hypogammaglobulinemia and a history of
recurrent sinus infections 7 years after the completion of
therapy. The symptoms resolved completely in response to
monthly intravenous immunoglobulin treatments.11 Finally,
rituximab has also been shown to delay immunologic recovery
after autologous transplantation, with low IgG levels at 2 years
post transplantation.13,14
The data from our phase 2 study show that blinatumomab-
mediated depletion of B cells and plasma blasts is reflected in
decreased serum concentrations of immunoglobulins during
and after treatment. Whereas naive B cells tended to be
regenerated soon after treatment, as suggested by recovery of
IgM levels, memory B cells and plasma cells might take longer to
reappear, based on the observation that recovery of IgG and IgA
levels was delayed after treatment. Infections associated with
B-cell–depleting therapies may occur during and after treatment
until full recovery of IgG levels, despite prior normalization of
peripheral B-cell counts owing to regeneration of naive, but not
memory, B cells. In the present study, grade 3 infections,
regardless of causal relationship to blinatumomab, were
reported in four out of the 21 patients (19%), with two (9.5%)
cases assessed as related to blinatumomab treatment. No
infection-related deaths occurred. Similarly, the rate of grade 3
or 4 infections during rituximab maintenance therapy for the
treatment of non-Hodgkin lymphoma was stated as 9.7%.15 A
review of blinatumomab data along with rituximab data
available in the literature does not suggest notable differences
in the long-term recovery of serum immunoglobulin levels. Of
note, it appears that rituximab therapy may cause a sustained
reduction of immunoglobulin concentrations in serum despite
the return of peripheral B cells, suggesting a similar regenera-
tion pattern as that proposed to follow blinatumomab
treatment. Additional depletion of plasma blasts by blinatumo-
mab, but not by rituximab, is not expected to be an issue as
these cells are comparably short-lived and, therefore, unable to
sustain normal immunoglobulin levels throughout and after
treatment. These cells, once again, have to differentiate out of
regenerated naive and memory B cells after treatment.
In summary, baseline and periodic monitoring of immuno-
globulin levels may be considered in patients who receive
antibody therapies against B-cell targets, such as blinatumomab.
Their suppressive effect on immunoglobulin levels appears to be
more pronounced than the suppressive effect of chemotherapy. In
patients with severe infections and low serum IgG concentrations,
IgG substitution treatment should be considered according to
local guidelines.
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